GSK’s Nucala Gains Approval in China for CRSwNP
GlaxoSmithKline ( (GSK) ) has provided an update. GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with ...
Daily6d
GSK Nucala approved in China for treatment of adults with chronic rhinosinusitis with nasal polyps
London: GSK plc has announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a ...
Pharmabiz6d
GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps
GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps: London, UK Saturday, January 4, 2025, 09:00 Hrs [IST] GSK plc announced ...
The Pharma Letter6d
GSK’s Nucala wins wider approval in China
China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK ...
GSK's Sinus Disease Drug Secures Approval In China
On Friday, the China National Medical Products Administration approved GSK plc (NYSE:GSK) Nucala (mepolizumab) as an add-on ...
GSK treatment approved for adults with sinus condition in China
(Alliance News) - GSK PLC on Friday reported that its Nucala treatment has been approved in China to treat long-term sufferers of a sinus ailment following a phase 3 study.
Businessworld11d
australia women's national cricket team vs south africa women's national cricket team stats
Jiangxi Shanxiang Pharmaceutical's first generic "Sorafenib" is about to be approved The results of Fujian's centralized procurement of medical consumables are announced, and Johnson & Johnson and ...
Businessworld11d
bharat rummy circle
INR:7444. bharat rummy circle GlaxoSmithKline's "Mepolizumab" is approved for listing in China Pharmaceutical and Health Industry Weekly Report (June 1st - Ju ...
Pharmaceutical Technology15d
Mepolizumab by GSK for Chronic Obstructive Pulmonary Disease (COPD): Likelihood of Approval
Mepolizumab is under clinical development by GSK and currently in Phase III for Chronic Obstructive Pulmonary Disease (COPD). According to GlobalData, Phase III drugs for Chronic Obstructive Pulmonary ...
Press Gazette22d
Top 50 news websites in the world: AP and NBC see more than 50% monthly surge
President Donald Trump talks to the media at a public press event following the RNC debate in Houston, Texas in February 2016. Picture: Stock_photo_world/Shutterstock ...
Daily29d
USFDA accepts GSK submission for use of Nucala in COPD
London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review, data from the MATINEE study to support the regulatory review process to obtain a new indication for the ...
pulmonologyadvisor29d
Mepolizumab Under Review for Eosinophilic COPD
The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for mepolizumab as an add-on maintenance treatment for chronic obstructive pulmonary disease ...